ID HCD2_MOUSE Reviewed; 261 AA. AC O08756; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 4. DT 08-NOV-2023, entry version 168. DE RecName: Full=3-hydroxyacyl-CoA dehydrogenase type-2; DE EC=1.1.1.35 {ECO:0000250|UniProtKB:Q99714}; DE AltName: Full=17-beta-estradiol 17-dehydrogenase; DE EC=1.1.1.62 {ECO:0000250|UniProtKB:Q99714}; DE AltName: Full=2-methyl-3-hydroxybutyryl-CoA dehydrogenase {ECO:0000250|UniProtKB:Q99714}; DE Short=MHBD {ECO:0000250|UniProtKB:Q99714}; DE AltName: Full=3-alpha-(17-beta)-hydroxysteroid dehydrogenase (NAD(+)); DE EC=1.1.1.239 {ECO:0000250|UniProtKB:Q99714}; DE AltName: Full=3-hydroxy-2-methylbutyryl-CoA dehydrogenase; DE EC=1.1.1.178 {ECO:0000250|UniProtKB:Q99714}; DE AltName: Full=3-hydroxyacyl-CoA dehydrogenase type II; DE AltName: Full=3alpha(or 20beta)-hydroxysteroid dehydrogenase; DE EC=1.1.1.53 {ECO:0000250|UniProtKB:Q99714}; DE AltName: Full=7-alpha-hydroxysteroid dehydrogenase; DE EC=1.1.1.159 {ECO:0000250|UniProtKB:Q99714}; DE AltName: Full=Endoplasmic reticulum-associated amyloid beta-peptide-binding protein; DE AltName: Full=Mitochondrial ribonuclease P protein 2; DE Short=Mitochondrial RNase P protein 2; DE AltName: Full=Short chain dehydrogenase/reductase family 5C member 1; DE AltName: Full=Short-chain type dehydrogenase/reductase XH98G2; DE AltName: Full=Type II HADH; GN Name=Hsd17b10; Synonyms=Erab, Hadh2; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Mus; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC STRAIN=C57BL/6 X CBA; RA Fu J., Chen X., Stern D., Yan S.D.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [2] RP PROTEIN SEQUENCE OF 2-6; 193-212 AND 215-226, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY. RC STRAIN=C57BL/6J; TISSUE=Liver; RA Bienvenut W.V.; RL Submitted (JUL-2005) to UniProtKB. RN [3] RP PROTEIN SEQUENCE OF 70-79 AND 131-147, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC STRAIN=C57BL/6J; TISSUE=Brain; RA Lubec G., Kang S.U.; RL Submitted (APR-2007) to UniProtKB. RN [4] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung, RC Pancreas, Spleen, and Testis; RX PubMed=21183079; DOI=10.1016/j.cell.2010.12.001; RA Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R., RA Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.; RT "A tissue-specific atlas of mouse protein phosphorylation and expression."; RL Cell 143:1174-1189(2010). RN [5] RP FUNCTION, AND DISRUPTION PHENOTYPE. RX PubMed=20077426; DOI=10.1002/emmm.200900055; RA Rauschenberger K., Schoeler K., Sass J.O., Sauer S., Djuric Z., Rumig C., RA Wolf N.I., Okun J.G., Koelker S., Schwarz H., Fischer C., Grziwa B., RA Runz H., Nuemann A., Shafqat N., Kavanagh K.L., Haemmerling G., RA Wanders R.J., Shield J.P., Wendel U., Stern D., Nawroth P., Hoffmann G.F., RA Bartram C.R., Arnold B., Bierhaus A., Oppermann U., Steinbeisser H., RA Zschocke J.; RT "A non-enzymatic function of 17beta-hydroxysteroid dehydrogenase type 10 is RT required for mitochondrial integrity and cell survival."; RL EMBO Mol. Med. 2:51-62(2010). RN [6] RP SUCCINYLATION [LARGE SCALE ANALYSIS] AT LYS-53; LYS-107 AND LYS-212, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic fibroblast, and Liver; RX PubMed=23806337; DOI=10.1016/j.molcel.2013.06.001; RA Park J., Chen Y., Tishkoff D.X., Peng C., Tan M., Dai L., Xie Z., Zhang Y., RA Zwaans B.M., Skinner M.E., Lombard D.B., Zhao Y.; RT "SIRT5-mediated lysine desuccinylation impacts diverse metabolic RT pathways."; RL Mol. Cell 50:919-930(2013). RN [7] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-53; LYS-69; LYS-99; LYS-105; RP LYS-107 AND LYS-212, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Liver; RX PubMed=23576753; DOI=10.1073/pnas.1302961110; RA Rardin M.J., Newman J.C., Held J.M., Cusack M.P., Sorensen D.J., Li B., RA Schilling B., Mooney S.D., Kahn C.R., Verdin E., Gibson B.W.; RT "Label-free quantitative proteomics of the lysine acetylome in mitochondria RT identifies substrates of SIRT3 in metabolic pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 110:6601-6606(2013). CC -!- FUNCTION: Mitochondrial dehydrogenase involved in pathways of fatty CC acid, branched-chain amino acid and steroid metabolism (By similarity). CC Acts as (S)-3-hydroxyacyl-CoA dehydrogenase in mitochondrial fatty acid CC beta-oxidation, a major degradation pathway of fatty acids. Catalyzes CC the third step in the beta-oxidation cycle, namely the reversible CC conversion of (S)-3-hydroxyacyl-CoA to 3-ketoacyl-CoA. Preferentially CC accepts straight medium- and short-chain acyl-CoA substrates with CC highest efficiency for (3S)-hydroxybutanoyl-CoA (By similarity). Acts CC as 3-hydroxy-2-methylbutyryl-CoA dehydrogenase in branched-chain amino CC acid catabolic pathway. Catalyzes the oxidation of 3-hydroxy-2- CC methylbutanoyl-CoA into 2-methyl-3-oxobutanoyl-CoA, a step in CC isoleucine degradation pathway (By similarity). Has hydroxysteroid CC dehydrogenase activity toward steroid hormones and bile acids. CC Catalyzes the oxidation of 3alpha-, 17beta-, 20beta- and 21- CC hydroxysteroids and 7alpha- and 7beta-hydroxy bile acids. Oxidizes CC allopregnanolone/brexanolone at the 3alpha-hydroxyl group, which is CC known to be critical for the activation of gamma-aminobutyric acid CC receptors (GABAARs) chloride channel. Has phospholipase C-like activity CC toward cardiolipin and its oxidized species (By similarity). Likely CC oxidizes the 2'-hydroxyl in the head group of cardiolipin to form a CC ketone intermediate that undergoes nucleophilic attack by water and CC fragments into diacylglycerol, dihydroxyacetone and orthophosphate. Has CC higher affinity for cardiolipin with oxidized fatty acids and may CC degrade these species during the oxidative stress response to protect CC cells from apoptosis (By similarity). By interacting with intracellular CC amyloid-beta, it may contribute to the neuronal dysfunction associated CC with Alzheimer disease (AD) (By similarity). Essential for structural CC and functional integrity of mitochondria (PubMed:20077426). CC {ECO:0000250|UniProtKB:Q99714, ECO:0000269|PubMed:20077426}. CC -!- FUNCTION: In addition to mitochondrial dehydrogenase activity, CC moonlights as a component of mitochondrial ribonuclease P, a complex CC that cleaves tRNA molecules in their 5'-ends. Together with CC TRMT10C/MRPP1, forms a subcomplex of the mitochondrial ribonuclease P, CC named MRPP1-MRPP2 subcomplex, which displays functions that are CC independent of the ribonuclease P activity. The MRPP1-MRPP2 subcomplex CC catalyzes the formation of N(1)-methylguanine and N(1)-methyladenine at CC position 9 (m1G9 and m1A9, respectively) in tRNAs; HSD17B10/MRPP2 CC acting as a non-catalytic subunit. The MRPP1-MRPP2 subcomplex also acts CC as a tRNA maturation platform: following 5'-end cleavage by the CC mitochondrial ribonuclease P complex, the MRPP1-MRPP2 subcomplex CC enhances the efficiency of 3'-processing catalyzed by ELAC2, retains CC the tRNA product after ELAC2 processing and presents the nascent tRNA CC to the mitochondrial CCA tRNA nucleotidyltransferase TRNT1 enzyme. CC Associates with mitochondrial DNA complexes at the nucleoids to CC initiate RNA processing and ribosome assembly. CC {ECO:0000250|UniProtKB:Q99714}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a (3S)-3-hydroxyacyl-CoA + NAD(+) = a 3-oxoacyl-CoA + H(+) + CC NADH; Xref=Rhea:RHEA:22432, ChEBI:CHEBI:15378, ChEBI:CHEBI:57318, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:90726; EC=1.1.1.35; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22433; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:22434; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(2S,3S)-3-hydroxy-2-methylbutanoyl-CoA + NAD(+) = 2-methyl-3- CC oxobutanoyl-CoA + H(+) + NADH; Xref=Rhea:RHEA:13281, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:57312, ChEBI:CHEBI:57335, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.178; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13282; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=NAD(+) + testosterone = androst-4-ene-3,17-dione + H(+) + CC NADH; Xref=Rhea:RHEA:14929, ChEBI:CHEBI:15378, ChEBI:CHEBI:16422, CC ChEBI:CHEBI:17347, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; CC EC=1.1.1.239; Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14930; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = 17beta- CC hydroxy-5alpha-androstan-3-one + H(+) + NADH; Xref=Rhea:RHEA:42004, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.53; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42006; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=17beta-estradiol + NAD(+) = estrone + H(+) + NADH; CC Xref=Rhea:RHEA:24612, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469, CC ChEBI:CHEBI:17263, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.62; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24613; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=cholate + NAD(+) = 3alpha,12alpha-dihydroxy-7-oxo-5beta- CC cholanate + H(+) + NADH; Xref=Rhea:RHEA:19409, ChEBI:CHEBI:11893, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:29747, ChEBI:CHEBI:57540, CC ChEBI:CHEBI:57945; EC=1.1.1.159; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19410; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(3S)-3-hydroxybutanoyl-CoA + NAD(+) = acetoacetyl-CoA + H(+) + CC NADH; Xref=Rhea:RHEA:30799, ChEBI:CHEBI:15378, ChEBI:CHEBI:57286, CC ChEBI:CHEBI:57316, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:30800; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:30801; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(3S)-hydroxyoctanoyl-CoA + NAD(+) = 3-oxooctanoyl-CoA + H(+) + CC NADH; Xref=Rhea:RHEA:31195, ChEBI:CHEBI:15378, ChEBI:CHEBI:57540, CC ChEBI:CHEBI:57945, ChEBI:CHEBI:62617, ChEBI:CHEBI:62619; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:31196; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:31197; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(3S)-hydroxyhexadecanoyl-CoA + NAD(+) = 3-oxohexadecanoyl-CoA CC + H(+) + NADH; Xref=Rhea:RHEA:31159, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57349, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, CC ChEBI:CHEBI:62613; Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:31160; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:31161; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=17beta-hydroxy-5alpha-androstan-3-one + NAD(+) = 5alpha- CC androstan-3,17-dione + H(+) + NADH; Xref=Rhea:RHEA:41992, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15994, ChEBI:CHEBI:16330, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41993; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=5alpha-pregnan-20beta-ol-3-one + NAD(+) = 5alpha- CC pregnane-3,20-dione + H(+) + NADH; Xref=Rhea:RHEA:42008, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:28952, ChEBI:CHEBI:57540, CC ChEBI:CHEBI:57945, ChEBI:CHEBI:78594; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42009; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=3alpha-hydroxy-5alpha-pregnan-20-one + NAD(+) = 5alpha- CC pregnane-3,20-dione + H(+) + NADH; Xref=Rhea:RHEA:41980, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:28952, ChEBI:CHEBI:50169, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41981; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=cortisone + NAD(+) = 17alpha-hydroxypregn-4-en-3,11,20-trione- CC 21-al + H(+) + NADH; Xref=Rhea:RHEA:42016, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:16962, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, CC ChEBI:CHEBI:78596; Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42017; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=11-dehydrocorticosterone + NAD(+) = H(+) + NADH + pregn-4-ene- CC 3,11,20,21-tetraone; Xref=Rhea:RHEA:42020, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:78600, CC ChEBI:CHEBI:78601; Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42021; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=cortisol + NAD(+) = 11beta,17alpha-dihydroxypregn-4- CC ene-3,20,21-trione + H(+) + NADH; Xref=Rhea:RHEA:42012, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:17650, ChEBI:CHEBI:57540, CC ChEBI:CHEBI:57945, ChEBI:CHEBI:78595; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42013; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=chenodeoxycholate + NAD(+) = 7-oxolithocholate + H(+) + NADH; CC Xref=Rhea:RHEA:42036, ChEBI:CHEBI:15378, ChEBI:CHEBI:36234, CC ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:78605; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42037; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=NAD(+) + ursodeoxycholate = 7-oxolithocholate + H(+) + NADH; CC Xref=Rhea:RHEA:42028, ChEBI:CHEBI:15378, ChEBI:CHEBI:57540, CC ChEBI:CHEBI:57945, ChEBI:CHEBI:78604, ChEBI:CHEBI:78605; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42029; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- CATALYTIC ACTIVITY: CC Reaction=3beta,7beta-dihydroxy-5beta-cholan-24-oate + NAD(+) = 3beta- CC hydroxy-7-oxo-5beta-cholan-24-oate + H(+) + NADH; CC Xref=Rhea:RHEA:42024, ChEBI:CHEBI:15378, ChEBI:CHEBI:57540, CC ChEBI:CHEBI:57945, ChEBI:CHEBI:78602, ChEBI:CHEBI:78603; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42025; CC Evidence={ECO:0000250|UniProtKB:Q99714}; CC -!- PATHWAY: Amino-acid degradation; L-isoleucine degradation. CC {ECO:0000250|UniProtKB:Q99714}. CC -!- PATHWAY: Lipid metabolism; fatty acid beta-oxidation. CC {ECO:0000250|UniProtKB:Q99714}. CC -!- PATHWAY: Steroid metabolism. {ECO:0000250|UniProtKB:Q99714}. CC -!- PATHWAY: Lipid metabolism; bile acid biosynthesis. CC {ECO:0000250|UniProtKB:Q99714}. CC -!- SUBUNIT: Homotetramer. Component of mitochondrial ribonuclease P, a CC complex composed of TRMT10C/MRPP1, HSD17B10/MRPP2 and PRORP/MRPP3. CC Interacts with TRMT10C/MRPP1; forming the MRPP1-MRPP2 subcomplex of the CC mitochondrial ribonuclease P complex. {ECO:0000250|UniProtKB:Q99714}. CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000250|UniProtKB:Q99714}. CC Mitochondrion matrix, mitochondrion nucleoid CC {ECO:0000250|UniProtKB:Q99714}. CC -!- DISRUPTION PHENOTYPE: Conditional knockout mice are fertile but rapidly CC die around week 26. Mitochondrial morphology is severely altered in the CC central and peripheral nervous system, as well as in the cerebellum. CC {ECO:0000269|PubMed:20077426}. CC -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases (SDR) CC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB57689.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96116; AAB57689.1; ALT_INIT; mRNA. DR CCDS; CCDS30471.1; -. DR AlphaFoldDB; O08756; -. DR SMR; O08756; -. DR IntAct; O08756; 22. DR MINT; O08756; -. DR STRING; 10090.ENSMUSP00000026289; -. DR BindingDB; O08756; -. DR ChEMBL; CHEMBL4295650; -. DR iPTMnet; O08756; -. DR PhosphoSitePlus; O08756; -. DR SwissPalm; O08756; -. DR EPD; O08756; -. DR jPOST; O08756; -. DR MaxQB; O08756; -. DR PaxDb; 10090-ENSMUSP00000026289; -. DR PeptideAtlas; O08756; -. DR ProteomicsDB; 269724; -. DR Pumba; O08756; -. DR AGR; MGI:1333871; -. DR MGI; MGI:1333871; Hsd17b10. DR eggNOG; KOG1199; Eukaryota. DR InParanoid; O08756; -. DR PhylomeDB; O08756; -. DR Reactome; R-MMU-70895; Branched-chain amino acid catabolism. DR UniPathway; UPA00221; -. DR UniPathway; UPA00364; -. DR UniPathway; UPA00659; -. DR ChiTaRS; Hsd17b10; mouse. DR PRO; PR:O08756; -. DR Proteomes; UP000000589; Unplaced. DR RNAct; O08756; Protein. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI. DR GO; GO:0005743; C:mitochondrial inner membrane; HDA:MGI. DR GO; GO:0042645; C:mitochondrial nucleoid; IDA:MGI. DR GO; GO:0030678; C:mitochondrial ribonuclease P complex; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0043527; C:tRNA methyltransferase complex; ISO:MGI. DR GO; GO:0044594; F:17-beta-hydroxysteroid dehydrogenase (NAD+) activity; ISS:UniProtKB. DR GO; GO:0047015; F:3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity; ISS:UniProtKB. DR GO; GO:0003857; F:3-hydroxyacyl-CoA dehydrogenase activity; ISS:UniProtKB. DR GO; GO:0018454; F:acetoacetyl-CoA reductase activity; ISO:MGI. DR GO; GO:0001540; F:amyloid-beta binding; ISO:MGI. DR GO; GO:0047044; F:androstan-3-alpha,17-beta-diol dehydrogenase activity; IEA:UniProtKB-EC. DR GO; GO:0106281; F:chenodeoxycholate 7-alpha-dehydrogenase (NAD+) activity; ISS:UniProtKB. DR GO; GO:0008709; F:cholate 7-alpha-dehydrogenase activity; ISS:UniProtKB. DR GO; GO:0004303; F:estradiol 17-beta-dehydrogenase [NAD(P)] activity; ISO:MGI. DR GO; GO:0042802; F:identical protein binding; ISO:MGI. DR GO; GO:0106282; F:isoursodeoxycholate 7-beta-dehydrogenase (NAD+) activity; ISS:UniProtKB. DR GO; GO:0051287; F:NAD binding; ISO:MGI. DR GO; GO:0030331; F:nuclear estrogen receptor binding; ISO:MGI. DR GO; GO:0005496; F:steroid binding; ISO:MGI. DR GO; GO:0047035; F:testosterone dehydrogenase (NAD+) activity; ISS:UniProtKB. DR GO; GO:0030283; F:testosterone dehydrogenase [NAD(P)] activity; ISS:UniProtKB. DR GO; GO:0000049; F:tRNA binding; ISS:UniProtKB. DR GO; GO:0106283; F:ursodeoxycholate 7-beta-dehydrogenase (NAD+) activity; ISS:UniProtKB. DR GO; GO:0008209; P:androgen metabolic process; ISS:UniProtKB. DR GO; GO:0006699; P:bile acid biosynthetic process; ISS:UniProtKB. DR GO; GO:0062173; P:brexanolone metabolic process; ISS:UniProtKB. DR GO; GO:0008207; P:C21-steroid hormone metabolic process; ISS:UniProtKB. DR GO; GO:0008210; P:estrogen metabolic process; ISS:UniProtKB. DR GO; GO:0006635; P:fatty acid beta-oxidation; ISS:UniProtKB. DR GO; GO:0006631; P:fatty acid metabolic process; IBA:GO_Central. DR GO; GO:0006550; P:isoleucine catabolic process; ISS:UniProtKB. DR GO; GO:1990180; P:mitochondrial tRNA 3'-end processing; ISS:UniProtKB. DR GO; GO:0097745; P:mitochondrial tRNA 5'-end processing; ISS:UniProtKB. DR GO; GO:0070901; P:mitochondrial tRNA methylation; ISS:UniProtKB. DR GO; GO:0007005; P:mitochondrion organization; ISO:MGI. DR GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB. DR CDD; cd05371; HSD10-like_SDR_c; 1. DR Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1. DR InterPro; IPR036291; NAD(P)-bd_dom_sf. DR InterPro; IPR020904; Sc_DH/Rdtase_CS. DR InterPro; IPR002347; SDR_fam. DR PANTHER; PTHR43658:SF8; 3-HYDROXYACYL-COA DEHYDROGENASE TYPE-2; 1. DR PANTHER; PTHR43658; SHORT-CHAIN DEHYDROGENASE/REDUCTASE; 1. DR Pfam; PF00106; adh_short; 1. DR PRINTS; PR00081; GDHRDH. DR PRINTS; PR00080; SDRFAMILY. DR SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1. DR PROSITE; PS00061; ADH_SHORT; 1. DR SWISS-2DPAGE; O08756; -. PE 1: Evidence at protein level; KW Acetylation; Direct protein sequencing; Fatty acid metabolism; KW Lipid metabolism; Mitochondrion; Mitochondrion nucleoid; NAD; KW Oxidoreductase; Reference proteome; Steroid metabolism; tRNA processing. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.2" FT CHAIN 2..261 FT /note="3-hydroxyacyl-CoA dehydrogenase type-2" FT /id="PRO_0000054811" FT ACT_SITE 168 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU10001" FT BINDING 20 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 41 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 65 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 91 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 155 FT /ligand="substrate" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 168 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 172 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 201 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT BINDING 203 FT /ligand="NAD(+)" FT /ligand_id="ChEBI:CHEBI:57540" FT /evidence="ECO:0000250|UniProtKB:Q99714" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.2" FT MOD_RES 53 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:23576753" FT MOD_RES 53 FT /note="N6-succinyllysine; alternate" FT /evidence="ECO:0007744|PubMed:23806337" FT MOD_RES 69 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:23576753" FT MOD_RES 99 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:23576753" FT MOD_RES 105 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:23576753" FT MOD_RES 107 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:23576753" FT MOD_RES 107 FT /note="N6-succinyllysine; alternate" FT /evidence="ECO:0007744|PubMed:23806337" FT MOD_RES 212 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:23576753" FT MOD_RES 212 FT /note="N6-succinyllysine; alternate" FT /evidence="ECO:0007744|PubMed:23806337" SQ SEQUENCE 261 AA; 27419 MW; 61213B13E2839D41 CRC64; MAAAVRSVKG LVAVVTGGAS GPWLATAKRL VGQGATAVLL DVPDSEGESQ AKKLGESCIF APANVTSEKE IQAALTLAKE KFGRIDVAVN CAGIAVAIKT YHQKKNKIHT LEDFQRVINV NLIGTFNVIR LVAGEMGQNE PDQGGQRGVI INTASVAAFE GQVGQAAYSA SKGGIDGMTL PIARDLAPTG IRVVTIAPGL FATPLLTTLP EKVRNFLASQ VPFPSRLGDP AEYAHLVQTI IENPFLNGEV IRLDGAIRMQ P //